GlaxoSmithKline says it’s still committed to investing in Stevenage despite announcing redundancies

The job losses will happen in the coming months.

The job losses will happen in the coming months. - Credit: Archant

A pharmaceuticals giant is making redundancies at its Stevenage site as part of a global restructuring programme.

GlaxoSmithKline announced in December that it’s changing its research and development organisation, which will mean jobs losses in the coming months, but says it’s still committed to the future of the Gunnels Wood Road site.

A spokesman for the firm said: “While there will be some job losses we’re also making investments and building new capabilities that will create new roles.

“We will be doing all we can to minimise job losses, including supporting those displaced from current roles to apply for the new ones being created.

“We’re committed to continuing our significant research and development operations in the Stevenage area – it’s one of our two global centres and critical to the future of our medicines pipeline.”


You may also want to watch:


The restructuring programme also aims to modernise the firm’s research and development programme.

It is not currently known how many redundancies will be required.

Most Read

Become a Supporter

This newspaper has been a central part of community life for many years. Our industry faces testing times, which is why we're asking for your support. Every contribution will help us continue to produce local journalism that makes a measurable difference to our community.

Become a Supporter